EyePoint (EYPT) Cash from Investing Activities (2010 - 2026)
EyePoint (EYPT) posted Cash from Investing Activities of $59.1 million for Q1 2026, up 179.09% sequentially from -$74.7 million in Q4 2025, and up 49.41% YoY from $39.5 million in Q1 2025.
Analysis
EyePoint (EYPT) Cash from Investing Activities (2010 - 2026) Analysis & Trends
EyePoint has reported Cash from Investing Activities for 17 years, with the latest figure at $59.1 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 49.41% year-over-year to $59.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.1 million (up 143.91% YoY) and the FY2025 annual result came in at $68.6 million, up 131.26% from the prior year.
- Cash from Investing Activities climbed to $59.1 million in Q1 2026 per EYPT's latest filing, from -$74.7 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $59.1 million in Q1 2026 and troughed at -$160.4 million in Q2 2024.
- A 5-year average of -$6.6 million and a median of $13.5 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 112325.0% in 2023, then tumbled 1291.02% in 2024.
- Over 5 years, Cash from Investing Activities stood at $32.9 million in 2022, then plunged by 243.23% to -$47.1 million in 2023, then tumbled by 103.53% to -$96.0 million in 2024, then grew by 22.19% to -$74.7 million in 2025, then jumped by 179.09% to $59.1 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $59.1 million, -$74.7 million, and $55.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 75.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.10 Mn |
| Mar 31, 2026 | 59.05 Mn |
| Dec 31, 2025 | -74.67 Mn |
| Sep 30, 2025 | 55.39 Mn |
| Jun 30, 2025 | 48.34 Mn |
| Mar 31, 2025 | 39.53 Mn |
| Dec 31, 2024 | -95.96 Mn |
| Sep 30, 2024 | 16.20 Mn |
| Jun 30, 2024 | -160.40 Mn |
| Mar 31, 2024 | 20.81 Mn |
| Dec 31, 2023 | -47.15 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Jun 30, 2023 | 13.47 Mn |
| Mar 31, 2023 | 32.09 Mn |
| Dec 31, 2022 | 32.92 Mn |
| Sep 30, 2022 | 6.27 Mn |
| Jun 30, 2022 | -12,000.00 |
| Mar 31, 2022 | -56.44 Mn |
| Dec 31, 2021 | -32.97 Mn |
| Sep 30, 2021 | -131,000.00 |